United Therapeutics (UTHR)PRESIDENT AND COO sold ~$7.03M
Michael Benkowitz, PRESIDENT AND COO at United Therapeutics, sold ~$7.03M of United Therapeutics shares.
- ~$7.03M
- Approx. value · 15K sh @ $480.75
- Traded
- Feb 17, 2026
- Filed
- Feb 19, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Dec 17, 2025Insider · 1 personInsiders: 2 sales (~$2.0M)
- Dec 18, 2025Insider · 2 peopleInsiders: 4 sales (~$2.5M)
- Dec 19, 2025Insider · 1 personInsiders: 2 sales (~$1.0M)
- Dec 22, 2025Insider · 2 peopleInsiders: 16 sales (~$14.6M)
- Dec 23, 2025InsiderDirector sold ~$26K of UTHR shares in the open market
- Dec 24, 2025Insider · 1 personInsiders: 7 sales (~$5.6M)
- Dec 29, 2025Insider · 1 personInsiders: 2 sales (~$11.3M)
- Jan 2, 2026Insider · 2 peopleInsiders: 9 sales (~$4.5M)
- Jan 5, 2026Insider · 2 peopleInsiders: 29 sales (~$11.0M)
- Jan 6, 2026InsiderDirector sold ~$510K of UTHR shares in the open market
- Jan 12, 2026Insider · 1 personInsiders: 2 sales (~$10.8M)
- Jan 15, 2026Insider · 1 personInsiders: 5 sales (~$3.9M)
- Jan 21, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On January 21, 2026, the Board of Directors (the “ Board ”) of United Therapeutics Corporation (the “ Company ”), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Kevin J. Tracey, M.D., to serve as a member of the Board.”
What came next
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for United Therapeutics
For United Therapeutics, OQRO holds 791 insider filings (SEC Form 4 or Form 144), 18 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its UTHR page.
Other recent filings by Michael Benkowitz, PRESIDENT AND COO
- SEC Form 4 at United Therapeutics (UTHR)Feb 25, 2026
- SEC Form 4 at United Therapeutics (UTHR)Feb 25, 2026
- SEC Form 4 at United Therapeutics (UTHR)Feb 19, 2026
- SEC Form 4 at United Therapeutics (UTHR)Feb 11, 2026
- SEC Form 4 at United Therapeutics (UTHR)Feb 11, 2026
The full history of Michael Benkowitz, PRESIDENT AND COO is on the profile page.
How this filing works
Other disclosures at United Therapeutics
- SEC Form 4Oct 9, 2026
- SEC Form 4Oct 9, 2026
- SEC Form 4Oct 9, 2026
- SEC Form 4Oct 9, 2026
- SEC Form 4Oct 9, 2026
- SEC Form 4Oct 9, 2026
Everything OQRO holds on this company is on its UTHR page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data